Reaping Pharmacological Benefits from the Oceans

Second of two articles Editor's Note: In the Sept. 27 issue of The Scientist, the author discussed some of the possibilities scientists have for generating medicinal products from organisms that live in the oceans.1 In this issue is a discussion of some of the problems and complexities involved in pursuing such possibilities. Despite the allure and promise the oceans hold for providing new medicines, virtually every aspect of pharmacological research from oceanic sources is more difficult and

Written byA. J. S. Rayl
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Second of two articles Editor's Note: In the Sept. 27 issue of The Scientist, the author discussed some of the possibilities scientists have for generating medicinal products from organisms that live in the oceans.1 In this issue is a discussion of some of the problems and complexities involved in pursuing such possibilities. Despite the allure and promise the oceans hold for providing new medicines, virtually every aspect of pharmacological research from oceanic sources is more difficult and intrinsically slower than land-based research. And the obstacles are not likely to change anytime soon. "There are a lot of concerns about what I call Rio Convention issues; that is, if you discover something in another country's waters, will you ever be able to develop it?" explains John Faulkner, a marine chemist at Scripps Institution of Oceanography. "Some countries nowadays are controlling all research in their waters, meaning, basically, we can't go there ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies